• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

血小板聚集阈指数评估复发性支架血栓形成患者血小板聚集能力的抑制作用。

The Inhibitory Effect of Platelet Aggregation Ability Assessed by the Platelet Aggregatory Threshold Index in a Patient with Recurrent Stent Thrombosis.

机构信息

Division of Cardiovascular Medicine, Department of Internal Medicine, Toho University, Japan.

Department of Cardiovascular Medicine, Toho University Graduate School of Medicine, Japan.

出版信息

Intern Med. 2024 May 15;63(10):1381-1386. doi: 10.2169/internalmedicine.2545-23. Epub 2023 Oct 6.

DOI:10.2169/internalmedicine.2545-23
PMID:37813611
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11157312/
Abstract

An 86-year-old man successfully underwent percutaneous coronary intervention (PCI), in which a drug-coated stent (DCS) was placed in the left anterior descending coronary artery. However, stent thrombosis occurred twice after eight and two months. After the second admission, the patient was tested for platelet aggregation activity using the platelet aggregation threshold index (PATI), and insufficient inhibition of platelet aggregation was observed. The patient's PATI improved to a satisfactory level using oral anticoagulants. At the six-month follow-up, clinical events were observed. Measuring the platelet aggregation ability can help clinicians understand the pathology of patients and determine treatment choices.

摘要

一位 86 岁男性成功接受了经皮冠状动脉介入治疗（PCI），在左前降支冠状动脉内植入了药物涂层支架（DCS）。然而，在 8 个月零 2 天后，支架内血栓形成了两次。第二次入院后，患者使用血小板聚集阈值指数（PATI）检测血小板聚集活性，观察到血小板聚集抑制不足。患者口服抗凝剂后 PATI 改善至满意水平。在 6 个月的随访中，观察到临床事件。测量血小板聚集能力有助于临床医生了解患者的病理，并确定治疗选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/d60a32681c67/1349-7235-63-1381-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/c3e23eef73ad/1349-7235-63-1381-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/bb6f95b4a1b7/1349-7235-63-1381-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/46b34c6c6410/1349-7235-63-1381-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/d60a32681c67/1349-7235-63-1381-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/c3e23eef73ad/1349-7235-63-1381-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/bb6f95b4a1b7/1349-7235-63-1381-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/46b34c6c6410/1349-7235-63-1381-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9c18/11157312/d60a32681c67/1349-7235-63-1381-g004.jpg

相似文献

1
The Inhibitory Effect of Platelet Aggregation Ability Assessed by the Platelet Aggregatory Threshold Index in a Patient with Recurrent Stent Thrombosis.血小板聚集阈指数评估复发性支架血栓形成患者血小板聚集能力的抑制作用。
Intern Med. 2024 May 15;63(10):1381-1386. doi: 10.2169/internalmedicine.2545-23. Epub 2023 Oct 6.
2
Platelet Reactivity and Clinical Outcomes After Coronary Artery Implantation of Drug-Eluting Stents in Subjects With Peripheral Arterial Disease: Analysis From the ADAPT-DES Study (Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents).外周动脉疾病患者冠状动脉植入药物洗脱支架后的血小板反应性及临床结局：来自ADAPT-DES研究（药物洗脱支架双重抗血小板治疗评估）的分析
Circ Cardiovasc Interv. 2017 Mar;10(3). doi: 10.1161/CIRCINTERVENTIONS.116.004904.
3
Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention: Results From the European PREvention of Stent Thrombosis by an Interdisciplinary Global European Effort Registry.接受直接经皮冠状动脉介入治疗的冠状动脉支架血栓形成所致 ST 段抬高型心肌梗死患者血小板反应性的观察性研究：来自欧洲跨学科全球努力预防支架血栓形成登记研究的结果。
JACC Cardiovasc Interv. 2017 Dec 26;10(24):2548-2556. doi: 10.1016/j.jcin.2017.09.019.
4
Platelet aggregation and the risk of stent thrombosis or bleeding in elective percutaneous coronary intervention patients.择期经皮冠状动脉介入治疗患者的血小板聚集与支架内血栓形成或出血风险
Blood Coagul Fibrinolysis. 2017 Jul;28(5):383-388. doi: 10.1097/MBC.0000000000000614.
5
Prasugrel in Clopidogrel Nonresponders Undergoing Percutaneous Coronary Intervention: The RECLOSE-3 Study (REsponsiveness to CLOpidogrel and StEnt Thrombosis).普拉格雷在经皮冠状动脉介入治疗中氯吡格雷无应答者中的应用：RE-CLOSE-3 研究（氯吡格雷反应和支架血栓形成）。
JACC Cardiovasc Interv. 2015 Oct;8(12):1563-70. doi: 10.1016/j.jcin.2015.07.010. Epub 2015 Sep 17.
6
Platelet reactivity and cardiovascular events after percutaneous coronary intervention in patients with stable coronary artery disease: the Stent Thrombosis In Belgium (STIB) trial.稳定性冠状动脉疾病患者经皮冠状动脉介入治疗后的血小板反应性与心血管事件：比利时支架血栓形成（STIB）试验
EuroIntervention. 2014 Jun;10(2):204-11. doi: 10.4244/EIJV10I2A34.
7
Late stent thrombosis of a second-generation drug- eluting stent.第二代药物洗脱支架的晚期支架内血栓形成。
J Invasive Cardiol. 2012 Oct;24(10):E225-7.
8
Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study.药物洗脱支架冠状动脉植入后血小板反应性与临床结局（ADAPT-DES）：一项前瞻性多中心登记研究。
Lancet. 2013 Aug 17;382(9892):614-23. doi: 10.1016/S0140-6736(13)61170-8. Epub 2013 Jul 26.
9
Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis.使用即时检测分析评估氯吡格雷治疗后的血小板反应性及早期药物洗脱支架血栓形成。
J Am Coll Cardiol. 2009 Mar 10;53(10):849-56. doi: 10.1016/j.jacc.2008.11.030.
10
Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.常规评估氯吡格雷抵抗血小板活性和基因多态性在预测药物洗脱支架植入术后稳定型冠状动脉疾病患者的临床结局。
JACC Cardiovasc Interv. 2013 Nov;6(11):1166-75. doi: 10.1016/j.jcin.2013.06.010.

本文引用的文献

1
Coronary Stent Thrombosis- Predictors and Prevention.冠状动脉支架血栓形成的预测因素和预防。
Dtsch Arztebl Int. 2020 May 1;117(18):320-326. doi: 10.3238/arztebl.2020.0320.
2
First evidence: rivaroxaban and apixaban reduce thrombin-dependent platelet aggregation.初步证据表明：利伐沙班和阿哌沙班可减少凝血酶依赖性血小板聚集。
J Thromb Thrombolysis. 2018 Oct;46(3):393-398. doi: 10.1007/s11239-018-1709-z.
3
Early restenose in a polymer-free Biolimus A9-coated stent (BioFreedom): A case report based on optical coherence tomography.无聚合物的生物雷帕霉素A9涂层支架（BioFreedom）早期再狭窄：基于光学相干断层扫描的病例报告
Cardiovasc Revasc Med. 2017 Apr-May;18(3):207-211. doi: 10.1016/j.carrev.2016.08.015. Epub 2016 Sep 6.
4
Ticagrelor vs. clopidogrel in Japanese, Korean and Taiwanese patients with acute coronary syndrome -- randomized, double-blind, phase III PHILO study.替格瑞洛与氯吡格雷用于日本、韩国及台湾地区急性冠脉综合征患者的比较——随机、双盲、III期PHILO研究
Circ J. 2015;79(11):2452-60. doi: 10.1253/circj.CJ-15-0112. Epub 2015 Sep 16.
5
First report of a subacute stent thrombosis in a prasugrel resistant patient successfully managed with ticagrelor.普拉格雷抵抗患者发生亚急性支架内血栓形成，使用替卡格雷成功治疗的首例报告。
Platelets. 2014;25(8):636-8. doi: 10.3109/09537104.2013.852659. Epub 2013 Nov 18.
6
Cytochrome P450 2B6 and 2C9 genotype polymorphism--a possible cause of prasugrel low responsiveness.细胞色素 P450 2B6 和 2C9 基因多态性——普拉格雷低反应性的可能原因。
Thromb Haemost. 2013 Jul;110(1):131-40. doi: 10.1160/TH13-01-0021. Epub 2013 Apr 25.
7
Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data.经皮冠状动脉介入治疗后血小板反应性对临床结局的影响：个体参与者数据的协作荟萃分析。
J Am Coll Cardiol. 2011 Nov 1;58(19):1945-54. doi: 10.1016/j.jacc.2011.06.059.
8
Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization.晚期药物洗脱支架血栓形成的病理相关性：支架小梁覆盖率作为内皮化的标志物
Circulation. 2007 May 8;115(18):2435-41. doi: 10.1161/CIRCULATIONAHA.107.693739. Epub 2007 Apr 16.
9
Interactions of two major metabolites of prasugrel, a thienopyridine antiplatelet agent, with the cytochromes P450.噻吩并吡啶类抗血小板药物普拉格雷的两种主要代谢产物与细胞色素P450的相互作用。
Drug Metab Dispos. 2006 Apr;34(4):600-7. doi: 10.1124/dmd.105.007989. Epub 2006 Jan 13.
10
Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method.通过筛滤压力法，使用新型全血凝集仪评估抗血小板药物对人血小板聚集的影响。
Br J Pharmacol. 2001 Aug;133(8):1396-404. doi: 10.1038/sj.bjp.0704204.